• Canagliflozin Workflows for Renal Research

  2026-09-02

  Build renal and metabolic assays around Canagliflozin’s selective SGLT2 activity, then extend glucose measurements with mitochondrial structure, respiration, and albuminuria endpoints. This practical workflow emphasizes solvent control, sex-aware analysis, and model-specific interpretation for more informative diabetes and kidney studies.

• Diphenyleneiodonium chloride in Cell Assays

  2026-09-02

  Diphenyleneiodonium chloride (DPI), SKU B6326, can help researchers separate redox-enzyme effects from assay artifacts in viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers mechanism, solvent compatibility, protocol design, interpretation, and practical vendor selection.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-01

  The reference study identifies CD44 as a metabolic dependency created by IDH mutation in leukemia. Its results connect CD44-driven glucose rerouting to NADPH supply and R-2HG production, supporting combined targeting of mutant IDH and CD44 as a strategy for acute myeloid leukemia research.

• Fenipentol: From Chuanxiong Signal to Translation

  2026-09-01

  Fenipentol (1-Phenyl-1-pentanol) offers translational researchers a defined small-molecule entry point into secretory physiology, ESR1-linked signaling, and the source-resolved pharmacology of Ligusticum chuanxiong. This article connects mechanistic hypotheses with validation strategy, formulation discipline, toxicology context, and a differentiated path beyond conventional product-page descriptions.

• Angiotensin I/II (1-5) Protocol Guide

  2026-08-31

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research, including blood pressure and aldosterone-related assays. It is intended for validated cardiovascular or renal models and should not be treated as interchangeable with full-length angiotensin peptides or applied to unrelated signaling workflows without independent validation.

• 5-(N,N-dimethyl)-Amiloride in Endothelial Models

  2026-08-31

  Use 5-(N,N-dimethyl)-Amiloride hydrochloride as a pharmacological probe to connect Na+/H+ exchanger activity with intracellular pH regulation, endothelial barrier failure, and cardiac injury phenotypes. This workflow combines real-time ion measurements with permeability, signaling, and moesin assays while clearly separating established evidence from testable sepsis-model hypotheses.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-08-30

  The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also expose the activation-loop phospho-threonine to WIP1, accelerating dephosphorylation. Its structural and biochemical results introduce a conformation-focused strategy for improving kinase-inhibitor potency and specificity while clarifying how kinase state may influence phosphatase recognition.

• PKH26 Red Fluorescent Cell Linker Kit Guide

  2026-08-29

  The PKH26 Red Fluorescent Cell Linker Kit supports red fluorescent labeling of cell membrane lipid regions for cell tracing and proliferation-oriented assays. It is intended for membrane labeling in in vitro and in vivo workflows, not for intracellular targets or non-membrane labeling, and exact labeling conditions should be established from the kit instructions and cell-specific optimization.

• HyperScript RT SuperMix for qPCR in PDAC Research

  2026-08-28

  Translate PDAC cell-fate changes into reproducible qRT-PCR readouts with a thermally stable reverse transcriptase, mixed-primer initiation, and high RNA-input flexibility. The workflow is especially useful for tracking adipogenic conversion, EMT suppression, and low-abundance transcripts from limited samples.

• SAG and Embryonic Hedgehog Signaling

  2026-08-28

  SAG is a selective Smoothened receptor agonist for dissecting Hedgehog pathway behavior across developmental and regenerative models. This article explains how dose, developmental timing, and endpoint selection determine whether SAG reveals pathway biology, supports repair studies, or produces malformation phenotypes.

• Site-Specific PEGylation of IL-11 in Pulmonary Fibrosis

  2026-08-27

  A 2024 International Journal of Pharmaceutics study engineered IL-11 variants that retain IL-11Rα binding while selectively weakening GP130 engagement through site-specific PEGylation. The resulting receptor-biased analogs extended IL-11 exposure and reduced bleomycin-induced pulmonary fibrosis in mice, providing a useful framework for cytokine antagonist design.

• IWP-2: Context-Aware PORCN Inhibition

  2026-08-27

  IWP-2 is a potent Wnt production inhibitor for dissecting ligand-dependent pathway biology in cancer research. This article pairs PORCN pharmacology with cell-state-resolved assay logic to improve interpretation beyond routine proliferation and apoptosis measurements.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-08-26

  The Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, provides an affinity-purified reagent for detecting HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. It is for controlled research workflows only and should not be used for diagnosis, therapy, or unvalidated live-cell applications.

• SAR405 and the Energy Logic of Autophagy

  2026-08-26

  A mechanistic and translational framework for using SAR405, a selective Vps34 inhibitor, to resolve how energy stress, AMPK–ULK1 signaling, autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment intersect in research and cancer models.

• BV6: A Causal Assay Framework for IAP Biology

  2026-08-25

  BV6 is an IAP antagonist that helps researchers interrogate apoptosis, treatment sensitization, and disease-model responses. This guide adds a distinct assay-interpretation framework informed by mitochondrial apoptosis research, separating pathway engagement from phenotypic rescue.

8563 records 1/571 page Next 12345 下5页 Last page